Company Overview

​

GrayMatters Health (GMH) is a health technology company developing and marketing an interventional psychiatry suite powered by proprietary fMRI-Informed biomarkers. A growing community of behavioral health clinics across the US is building Prism programs for personalized patient care. 

​

GMH is the first company to develop digital brain region specific biomarkers for mental health. While medical biomarkers usually measure tissue to assess disease, our fMRI-Informed biomarkers measure brain activity associated with Depression and PTSD. These biomarkers were developed by harnessing advanced machine learning to register fMRI data from deep in the brain to readily accessible EEG. This innovation brings the power of evidence-based, precision self-neuromodulation to any psychiatry clinic.

​

​

​

​

​

​

​

​

​

​

​

​

​

​

 

Founded in 2018 by Oded Kraft, Rani Cohen and Shai Attia, GMH is on a mission to connect mental health disorders to their underlying brain mechanisms to improve patient care and outcomes. The company’s patented core technology was invented by Professor Talma Hendler, MD, PhD and her team at Tel Aviv University, with further development by GMH’s talented team of engineers. 

​​